{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:29:15Z","timestamp":1791584955063,"version":"4.3.4"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.prp.2026.156638","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T22:06:36Z","timestamp":1785708396000},"page":"156638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting T-cell exhaustion and tumour immune evasion: a review of emerging strategies"],"prefix":"10.1016","volume":"287","author":[{"given":"Leticija","family":"Saltis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liew Jun","family":"Mun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2026.156638_bib1","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.24783","article-title":"Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"92","author":"Aldoss","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.prp.2026.156638_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-019-1326-9","article-title":"TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection","volume":"571","author":"Alfei","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156638_bib3","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1016\/j.cell.2024.08.029","article-title":"Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy","volume":"187","author":"Baldwin","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156638_bib4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41586-022-05374-w","article-title":"Nociceptor neurons affect cancer immunosurveillance","volume":"611","author":"Balood","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156638_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: State of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.prp.2026.156638_bib6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.prp.2026.156638_bib7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-023-06537-z","article-title":"The power and potential of mitochondria transfer","volume":"623","author":"Borcherding","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156638_bib8","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s43018-025-01004-2","article-title":"Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and\/or metastatic squamous cell carcinomas: a phase 2 basket trial","volume":"6","author":"Borcoman","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.prp.2026.156638_bib9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","article-title":"An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer","volume":"36","author":"Burr","year":"2019","journal-title":"Cancer Cell."},{"key":"10.1016\/j.prp.2026.156638_bib10","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41568-019-0196-7","article-title":"Targeting transcription factors in cancer \u2014 from undruggable to reality","volume":"19","author":"Bushweller","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2026.156638_bib11","doi-asserted-by":"crossref","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a Titin-Derived HLA-A1\u2013Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3\u2013Directed T Cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.prp.2026.156638_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.prp.2026.156638_bib13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","article-title":"FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy","volume":"629","author":"Chan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156638_bib14","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156638_bib15","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.immuni.2019.09.013","article-title":"TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell fate decision","volume":"51","author":"Chen","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.prp.2026.156638_bib16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156638_bib17","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156638_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adh2605","article-title":"TOX2 coordinates with TET2 to positively regulate central memory differentiation in human CAR T cells","volume":"9","author":"Collins","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.prp.2026.156638_bib19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41541-026-01376-1","article-title":"Antigen cross-presentation potentiating cancer vaccine adjuvant for T cell expansion and synergy with anti-PD-1","volume":"11","author":"Dang","year":"2026","journal-title":"Npj Vaccin."},{"key":"10.1016\/j.prp.2026.156638_bib20","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2026.156638_bib21","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/15384101.2018.1442623","article-title":"Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors","volume":"17","author":"Daskalakis","year":"2018","journal-title":"Cell. Cycle"},{"key":"10.1016\/j.prp.2026.156638_bib22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumor immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.prp.2026.156638_bib23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","article-title":"FOXO1 is a master regulator of memory programming in CAR T cells","volume":"629","author":"Doan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156638_bib24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.prp.2026.156638_bib25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12935-020-01719-5","article-title":"The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment","volume":"21","author":"Emami Nejad","year":"2021","journal-title":"Cancer Cell. Int."},{"key":"10.1016\/j.prp.2026.156638_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.prp.2026.156638_bib27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","article-title":"De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation","volume":"170","author":"Ghoneim","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156638_bib28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41586-023-06568-6","article-title":"The \u03b21-adrenergic receptor links sympathetic nerves to T cell exhaustion","volume":"622","author":"Globig","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156638_bib29","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41590-022-01194-2","article-title":"TCF-1: A maverick in T cell development and function","volume":"23","author":"Gounari","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.prp.2026.156638_bib30","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1158\/1078-0432.CCR-19-1305","article-title":"Phase 1\/1b study of pembrolizumab plus vorinostat in advanced\/metastatic non-small cell lung cancer","volume":"25","author":"Gray","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156638_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adz4088","article-title":"Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent\u2013programmed CAR T cells","volume":"12","author":"Guo","year":"2026","journal-title":"Sci. Adv."},{"issue":"200","key":"10.1016\/j.prp.2026.156638_bib32","first-page":"1088","article-title":"Comparison of T cell activities mediated by human TCRs and CARs that use the same recognition domains","volume":"1950","author":"Harris","year":"2018","journal-title":"J. Immunol. Baltim. Md"},{"key":"10.1016\/j.prp.2026.156638_bib33","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/ijc.35347","article-title":"How many people in the US are eligible for and respond to checkpoint inhibitors: An empirical analysis","volume":"156","author":"Haslam","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.prp.2026.156638_bib34","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-20-3305","article-title":"Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti-PD-(L)1 therapy","volume":"27","author":"Hellmann","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.prp.2026.156638_bib35","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41573-020-0077-5","article-title":"Targeting the epigenetic regulation of antitumour immunity","volume":"19","author":"Hogg","year":"2020","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.prp.2026.156638_bib36","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41586-025-09176-8","article-title":"Nerve-to-cancer transfer of mitochondria during cancer metastasis","volume":"644","author":"Hoover","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156638_bib37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","article-title":"Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery","volume":"43","author":"Hu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156638_bib38","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1158\/2159-8290.CD-25-0587","article-title":"Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed\/Refractory NK\/T-cell Lymphoma","volume":"15","author":"Huang","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2026.156638_bib39","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41420-024-01895-7","article-title":"Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer","volume":"10","author":"Huang","year":"2024","journal-title":"Cell. Death Discov."},{"key":"10.1016\/j.prp.2026.156638_bib40","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1200\/JCO.2023.41.6_suppl.506","article-title":"A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183)","volume":"41","author":"Hussain","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156638_bib41","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41586-024-08439-0","article-title":"Immune evasion through mitochondrial transfer in the tumour microenvironment","volume":"638","author":"Ikeda","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156638_bib42","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156638_bib43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ccell.2024.11.006","article-title":"EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function","volume":"43","author":"Isshiki","year":"2025","journal-title":"Cancer Cell."},{"key":"10.1016\/j.prp.2026.156638_bib44","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2159-8290.CD-22-1319","article-title":"Disruption of SUV39H1-Mediated H3K9 Methylation Sustains CAR T-cell Function","volume":"14","author":"Jain","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2026.156638_bib45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13148-021-01069-7","article-title":"Advances in epigenetic therapeutics with focus on solid tumors","volume":"13","author":"Jin","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.prp.2026.156638_bib46","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2159-8290.CD-11-0214","article-title":"Combination epigenetic therapy has efficacy in patients with refractory advanced non\u2013small cell lung cancer","volume":"1","author":"Juergens","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1016\/j.prp.2026.156638_bib47","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1038\/s41388-022-02455-y","article-title":"Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype","volume":"41","author":"Kang","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2026.156638_bib48","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156638_bib49","doi-asserted-by":"crossref","first-page":"E1659","DOI":"10.1073\/pnas.1608448114","article-title":"NF\u03baB\u2013Pim-1\u2013Eomesodermin axis is critical for maintaining CD8 T-cell memory quality","volume":"114","author":"Knudson","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.prp.2026.156638_bib50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13148-021-01226-y","article-title":"Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis","volume":"14","author":"Kuang","year":"2022","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.prp.2026.156638_bib51","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2219086120","article-title":"Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion","volume":"120","author":"Lamarche","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.prp.2026.156638_bib52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13045-021-01209-9","article-title":"Born to survive: how cancer cells resist CAR T cell therapy","volume":"14","author":"Lemoine","year":"2021","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.prp.2026.156638_bib53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12929-024-00998-8","article-title":"Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies","volume":"31","author":"Li","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.prp.2026.156638_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adm8251","article-title":"DNMT1 inhibition reprograms T cells to NK-like cells with potent antitumor activity","volume":"10","author":"Li","year":"2025","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.prp.2026.156638_bib55","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.prp.2026.156638_bib56","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12943-023-01768-0","article-title":"Epigenetic reprogramming of Runx3 reinforces CD8\u2009+\u2009T-cell function and improves the clinical response to immunotherapy","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2026.156638_bib57","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41586-019-0979-8","article-title":"Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction","volume":"567","author":"Liu","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156638_bib58","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13148-021-01046-0","article-title":"Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy","volume":"13","author":"Lodewijk","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.prp.2026.156638_bib59","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.prp.2026.156638_bib60","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/2159-8290.CD-22-1350","article-title":"SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors","volume":"14","author":"L\u00f3pez-Cobo","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2026.156638_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj6251","article-title":"Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control","volume":"10","author":"Lu","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.prp.2026.156638_bib62","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/s41416-023-02267-1","article-title":"Phase I\/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors","volume":"128","author":"Luke","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2026.156638_bib63","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF-\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156638_bib64","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","article-title":"The transcription factor NFAT promotes exhaustion of activated CD8+ T cells","volume":"42","author":"Martinez","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.prp.2026.156638_bib65","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-11-3909","article-title":"Epigenetic Resensitization to Platinum in Ovarian Cancer","volume":"72","author":"Matei","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2026.156638_bib66","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156638_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abk1900","article-title":"TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models","volume":"15","author":"Meyran","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.prp.2026.156638_bib68","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.prp.2026.156638_bib69","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1038\/s41598-020-60409-4","article-title":"Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer","volume":"10","author":"Moufarrij","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2026.156638_bib70","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1038\/s41467-022-31504-z","article-title":"CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas","volume":"13","author":"Niborski","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156638_bib71","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.1229620","article-title":"Progenitor and Terminal Subsets of CD8+ T Cells Cooperate to Contain Chronic Viral Infection","volume":"338","author":"Paley","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.prp.2026.156638_bib72","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.clml.2021.12.014","article-title":"Combination of atezolizumab and tazemetostat in patients with relapsed\/refractory diffuse large B-cell lymphoma: results from a phase Ib study","volume":"22","author":"Palomba","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.prp.2026.156638_bib73","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.prp.2026.156638_bib74","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumor-specific T cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156638_bib75","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ccell.2025.01.013","article-title":"EZH1\/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models","volume":"43","author":"Porazzi","year":"2025","journal-title":"Cancer Cell."},{"key":"10.1016\/j.prp.2026.156638_bib76","doi-asserted-by":"crossref","first-page":"eabh0272","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.prp.2026.156638_bib77","article-title":"T cell killing does not require the formation of a stable mature immunological synapse","author":"Purbhoo","year":"2004","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.prp.2026.156638_bib78","doi-asserted-by":"crossref","DOI":"10.1172\/JCI181671","article-title":"Epigenetic therapy sensitizes anti\u2013PD-1 refractory head and neck cancers to immunotherapy rechallenge","volume":"135","author":"Qin","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prp.2026.156638_bib79","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1038\/s41467-024-48607-4","article-title":"Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells","volume":"15","author":"Qiu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156638_bib80","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156638_bib81","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156638_bib82","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","article-title":"The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction","volume":"45","author":"Scharping","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.prp.2026.156638_bib83","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156638_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.866339","article-title":"Comparison Between Nr4a Transcription Factor Regulation and Function in Lymphoid and Tumor Treg Cells","volume":"13","author":"Sekiya","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156638_bib85","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1126\/science.aae0491","article-title":"The epigenetic landscape of T cell exhaustion","volume":"354","author":"Sen","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.prp.2026.156638_bib86","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1126\/science.aae0491","article-title":"The epigenetic landscape of T cell exhaustion","volume":"354","author":"Sen","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.prp.2026.156638_bib87","doi-asserted-by":"crossref","first-page":"12410","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.prp.2026.156638_bib88","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40164-024-00504-8","article-title":"Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy","volume":"13","author":"Shao","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.prp.2026.156638_bib89","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.prp.2026.156638_bib90","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156638_bib91","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy","volume":"365","author":"Stasi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156638_bib92","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/sj.bjc.6604932","article-title":"Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo","volume":"100","author":"Steele","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2026.156638_bib93","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1182\/blood-2024-210370","article-title":"Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)","volume":"144","author":"Stempel","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.prp.2026.156638_bib94","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12575-025-00265-6","article-title":"Mechanisms of T-cell Depletion in Tumors and Advances in Clinical Research","volume":"27","author":"Su","year":"2025","journal-title":"Biol. Proced. Online"},{"key":"10.1016\/j.prp.2026.156638_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113392","article-title":"Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies","volume":"144","author":"Sun","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.prp.2026.156638_bib96","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1074-7613(00)80483-5","article-title":"Evidence that a Single Peptide\u2013MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response","volume":"4","author":"Sykulev","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.prp.2026.156638_bib97","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets","volume":"15","author":"Tie","year":"2022","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.prp.2026.156638_bib98","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41590-023-01614-x","article-title":"Activation of the transcription factor NFAT5 in the tumor microenvironment enforces CD8+ T cell exhaustion","volume":"24","author":"Till\u00e9","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.prp.2026.156638_bib99","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.prp.2026.156638_bib100","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/s43018-024-00729-w","article-title":"Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial","volume":"5","author":"Torres","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.prp.2026.156638_bib101","doi-asserted-by":"crossref","DOI":"10.1172\/JCI138560","article-title":"Entinostat induces antitumor immune responses through immune editing of tumor neoantigens","volume":"131","author":"Truong","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prp.2026.156638_bib102","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41401-025-01639-y","article-title":"DNMT inhibition epigenetically restores the cGAS-STING pathway and activates RIG-I\/MDA5-MAVS to enhance antitumor immunity","volume":"47","author":"Tu","year":"2026","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.prp.2026.156638_bib103","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","article-title":"Altered metabolism in cancer: insights into energy pathways and therapeutic targets","volume":"23","author":"Tufail","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2026.156638_bib104","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41590-020-0725-2","article-title":"Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen","volume":"21","author":"Vardhana","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.prp.2026.156638_bib105","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.immuni.2011.09.021","article-title":"The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation","volume":"35","author":"Wang","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.prp.2026.156638_bib106","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13578-023-01073-9","article-title":"Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms","volume":"13","author":"Wang","year":"2023","journal-title":"Cell. Biosci."},{"key":"10.1016\/j.prp.2026.156638_bib107","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12967-025-07645-2","article-title":"Cell-type specific activation of the cGAS-STING pathway in tumor immunotherapy: mechanisms and therapeutic implications","volume":"24","author":"Wang","year":"2026","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.prp.2026.156638_bib108","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156638_bib109","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","article-title":"HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade","volume":"3","author":"Woods","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.prp.2026.156638_bib110","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70089","article-title":"Targeting METTL3 as a checkpoint to enhance T cells for tumour immunotherapy","volume":"14","author":"Wu","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.prp.2026.156638_bib111","doi-asserted-by":"crossref","DOI":"10.1172\/JCI192928","article-title":"Targeting PIM2 improves antitumor immunity through promoting effector function and persistence of CD8 T cells","volume":"136","author":"Wu","year":"2026","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prp.2026.156638_bib112","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12943-024-02175-9","article-title":"Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells","volume":"23","author":"Yang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2026.156638_bib113","article-title":"T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities","author":"Yu","year":"2026","journal-title":"Adv. Sci."},{"key":"10.1016\/j.prp.2026.156638_bib114","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156638_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110079","article-title":"CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia","volume":"37","author":"Zebley","year":"2021","journal-title":"Cell. Rep."},{"key":"10.1016\/j.prp.2026.156638_bib116","doi-asserted-by":"crossref","DOI":"10.1177\/1533033819831068","article-title":"The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review","volume":"18","author":"Zhang","year":"2019","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.prp.2026.156638_bib117","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1158\/1078-0432.CCR-15-2584","article-title":"HDAC inhibitors enhance T-Cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma","volume":"22","author":"Zheng","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156638_bib118","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1158\/1078-0432.CCR-19-1351","article-title":"Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti\u2013PD-1 Resistance in Head and Neck Cancer","volume":"26","author":"Zhou","year":"2020","journal-title":"Clin. Cancer Res."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T06:37:29Z","timestamp":1788763049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826002918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":118,"alternative-id":["S0344033826002918"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156638","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting T-cell exhaustion and tumour immune evasion: a review of emerging strategies","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156638","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156638"}}